7MMN image
Entry Detail
PDB ID:
7MMN
Title:
Crystal Structure of the Prefusion RSV F Glycoprotein bound by human antibody AM14
Biological Source:
PDB Version:
Deposition Date:
2021-04-29
Release Date:
2021-09-08
Method Details:
Experimental Method:
Resolution:
3.57 Å
R-Value Free:
0.24
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Fusion glycoprotein F2
Chain IDs:D (auth: A), F (auth: C), H (auth: J)
Chain Length:72
Number of Molecules:3
Biological Source:Human respiratory syncytial virus
Polymer Type:polypeptide(L)
Description:Fusion glycoprotein F1,Fibritin
Chain IDs:E (auth: B), G (auth: I), I (auth: K)
Chain Length:414
Number of Molecules:3
Biological Source:Human respiratory syncytial virus, Enterobacteria phage T4
Polymer Type:polypeptide(L)
Description:AM14 Fab Light Chain
Chain IDs:A (auth: L), B (auth: E), C (auth: G)
Chain Length:219
Number of Molecules:3
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:AM14 Fab Heavy Chain
Chain IDs:J (auth: M), K (auth: H), L (auth: D)
Chain Length:244
Number of Molecules:3
Biological Source:Homo sapiens
Primary Citation
Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein.
Mabs 13 1955812 1955812 (2021)
PMID: 34420474 DOI: 10.1080/19420862.2021.1955812

Abstact

Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract infections resulting in medical intervention and hospitalizations during infancy and early childhood, and vaccination against RSV remains a public health priority. The RSV F glycoprotein is a major target of neutralizing antibodies, and the prefusion stabilized form of F (DS-Cav1) is under investigation as a vaccine antigen. AM14 is a human monoclonal antibody with the exclusive capacity of binding an epitope on prefusion F (PreF), which spans two F protomers. The quality of recognizing a trimer-specific epitope makes AM14 valuable for probing PreF-based immunogen conformation and functionality during vaccine production. Currently, only a low-resolution (5.5 Å) X-ray structure is available of the PreF-AM14 complex, revealing few reliable details of the interface. Here, we perform complementary structural studies using X-ray crystallography and cryo-electron microscopy (cryo-EM) to provide improved resolution structures at 3.6 Å and 3.4 Å resolutions, respectively. Both X-ray and cryo-EM structures provide clear side-chain densities, which allow for accurate mapping of the AM14 epitope on DS-Cav1. The structures help rationalize the molecular basis for AM14 loss of binding to RSV F monoclonal antibody-resistant mutants and reveal flexibility for the side chain of a key antigenic residue on PreF. This work provides the basis for a comprehensive understanding of RSV F trimer specificity with implications in vaccine design and quality assessment of PreF-based immunogens.

Legend

Protein

Chemical

Disease

Primary Citation of related structures